Therapeutic targeting of regulatory T cells enhances tumor-specific CD8+ T cell responses in Epstein–Barr virus associated nasopharyngeal carcinoma  by Fogg, Mark et al.
Virology 441 (2013) 107–113Contents lists available at SciVerse ScienceDirectVirology0042-68
http://d
n Corr
Fax: +1
E-m
1 Pr
Mount Sjournal homepage: www.elsevier.com/locate/yviroTherapeutic targeting of regulatory T cells enhances tumor-speciﬁc
CD8+ T cell responses in Epstein–Barr virus associated
nasopharyngeal carcinomaMark Fogg a, John R. Murphy c, Jochen Lorch d, Marshall Posner d,1, Fred Wang a,b,n
a Department of Medicine, Brigham and Women's Hospital, USA
b Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115, USA
c Departments of Medicine and Microbiology, Boston University School of Medicine, Boston, MA 02118, USA
d Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USAa r t i c l e i n f o
Article history:
Received 12 February 2013
Returned to author for revisions
6 March 2013
Accepted 20 March 2013
Available online 17 April 2013
Keywords:
Epstein–Barr virus
Nasopharyngeal carcinoma
CD8+ T cells
T regulatory cells
Ontak22/$ - see front matter & 2013 Elsevier Inc. A
x.doi.org/10.1016/j.virol.2013.03.016
espondence to: 181 Longwood Avenue, MC
617 525 4257.
ail address: fwang@research.bwh.harvard.edu
esent Address: The Tisch Cancer Institute, Hea
inai School of Medicine, 1 Gustave L. Levy Plaa b s t r a c t
Epstein–Barr virus (EBV) is associated with multiple malignancies including nasopharyngeal carcinoma
(NPC). In nasopharynx cancer, CD8+ T cells speciﬁc for EBV Nuclear Antigen-1 (EBNA-1) and Latent
Membrane Protein 2 (LMP2) are important components of anti-tumor immunity since both are
consistently expressed in NPC. We have previously shown that EBNA-1-speciﬁc CD8+ T cell responses
were suppressed in NPC patients compared to healthy controls. We now ﬁnd that CD8+ T cell responses
speciﬁc for LMP2 are also abnormal in NPC patients, and both EBNA-1- and LMP2-speciﬁc responses are
suppressed by regulatory T cells (Treg). EBNA-1 and LMP2-speciﬁc CD8+ T cell responses, as well as
immune control of EBV-infected cells in vitro, could be restored by the depletion of Tregs and by use of a
clinically approved drug targeting Tregs. Thus, in vivo modulation of Tregs may be an effective means of
enhancing these anti-tumor immune responses in NPC patients.
& 2013 Elsevier Inc. All rights reserved.Introduction
Epstein–Barr virus (EBV) is a herpesvirus that infects nearly all
humans by adulthood. Primary infection usually occurs early in
life, and EBV infection is controlled, but not eliminated, by the host
immune response resulting in a lifelong, asymptomatic, persistent
infection (Rickinson and Kieff, 2007). Occasionally, persistent EBV
infection is complicated by the development of EBV-positive
malignancies such as Hodgkin Lymphoma (HL) and nasopharyn-
geal carcinoma (NPC).
Viral proteins expressed in these tumors are immunogenic,
non-self tumor antigens, yet anti-viral immunity may be unable to
prevent or eradicate these virus associated tumors for multiple
reasons. Both HL and NPC express a limited number of viral
proteins, EBV Nuclear Antigen-1 (EBNA-1), and two Latent Mem-
brane Proteins (LMP1 and LMP2) (Deacon et al., 1993; Murray
et al., 1996; Niedobitek et al., 1992), and the CD8+ T cell response
directed toward these proteins are sub-dominant (Hislop et al.,
2007). Discovering ways to increase EBV-speciﬁc, anti-tumor CD8
+ T cells is an active area of investigation for vaccine developmentll rights reserved.
P8, Boston, MA 02115, USA.
(F. Wang).
d and Neck Oncology Center,
ce, Box 1128, NY 10029, USA.and immunotherapeutics against EBV-associated cancers (Smith
et al., 2012; Louis et al., 2009; Di Stasi et al., 2009).
A suppressive tumor microenvironment can also represent a
signiﬁcant barrier to successful anti-tumor immunity by inhibiting
the EBV-speciﬁc CD8+ T cell response against EBV-infected malig-
nancies. HL is characterized by an inﬂammatory cell inﬁltrate
surrounding Reed–Sternberg cells with robust expression of
immunosuppressive cytokines (Marshall et al., 2004). NPC is also
referred to as a lymphoepithelioma due to inﬁltration of tumors
with T cells (Herait et al., 1987) that create an immunosuppressive
environment (Klibi et al., 2009). Identifying and overcoming
pathways in NPC and HL patients that suppress EBV-speciﬁc
immunity may provide a synergistic mechanism for improving
therapy of EBV-associated malignancies.
We previously reported that EBNA-1-speciﬁc CD8+ T cell
responses from the majority of NPC patients were abnormal
because they failed to respond to their own EBV-infected B cells
(Fogg et al., 2009). EBNA-1-speciﬁc CD8+ T cells could be
expanded by stimulation with peptides derived from EBNA-1 in
the presence of cytokines, thus indicating the abnormality in NPC
patients was not due to a lack of EBNA-1-speciﬁc CD8+ T cells.
Instead, the data suggested EBNA-1-speciﬁc CD8+ T cells were
being suppressed in the presence of EBV-infected cells. In the
current study, we ﬁnd that this immune abnormality in NPC
patients extends to CD8+ T cell responses speciﬁc for LMP2,
another viral protein expressed in NPC. Furthermore, we identify
that EBNA-1- and LMP2-speciﬁc CD8+ T cell responses are
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responses is reversible in many cases by depletion of Tregs. Under-
standing the extent, prevalence, and mechanism of this suppression
may be important for developing new immune therapies for NPC.Results
Abnormal LMP2-speciﬁc CD8+ T cell responses to EBV-infected cells
in NPC patients
We evaluated the in vitro expansion of LMP2-speciﬁc CD8+
T cells after stimulation with autologous, EBV transformed lym-
phoblastoid B cell lines versus LMP2 peptides in NPC patients and
healthy donors. We identiﬁed the LMP2 epitopes recognized by
EBV- and peptide-stimulated T cell lines to ask whether the
repertoire of LMP2-speciﬁc CD8+ T cells from NPC patients was
the same after EBV versus peptide stimulation.
First, PBMC from 27 NPC patients were repetitively stimulated
with their irradiated LCL to generate EBV-stimulated T cell lines
(Fogg et al., 2009; Straathof et al., 2005). LMP2-speciﬁc CD8+ T cell
epitopes were identiﬁed in the EBV-stimulated T cell lines by
incubation with individual LMP2 peptides in IFN-γ ELISPOT assays
(Fig. 1A, black bars). Four NPC patients had no LMP2-speciﬁc T cell
responses (NPC13, 35, 44, and 43). Sixteen patients recognized aFig. 1. Repertoire of the LMP2-speciﬁc CD8+ T cell response in NPC patients and healthy
NPC patients (A) and healthy donors (B) in T cell lines stimulated with LCL (black bars) or
were identiﬁed by responses to individual LMP2 peptides in IFN-γ ELISPOT assays and (C)
are shown. Statistical signiﬁcance was determined by Students t test.single epitope (NPC8, 11, 15, 30, 31, 45, 6, 27, 34, 39, 42, 14, 26, 1, 29,
and 2), and seven NPC patients recognized 2 epitopes (NPC17, 38,
46, 9, 12, 19, and 4) for an average of 1.1 epitopes per NPC patient
recognized by CD8+ T cells after stimulation with LCL.
Next, PBMC from the same NPC patients were stimulated with
a pool of overlapping LMP2 peptides in the presence of cytokines
to generate peptide-stimulated T cells. After 10–14 days the
peptide-stimulated lines were depleted of CD4+ T cells, and the
number of LMP2 epitopes recognized by the LMP2-speciﬁc CD8+
T cell response was determined. Strikingly, in 15 patients, peptide-
stimulated T cells recognized more LMP2 epitopes than the EBV-
stimulated T cells (Fig. 1A, white bars versus black bars, NPC43, 6,
27, 34, 39, 42, 14, 26, 1, 29, 2, 9, 12, 19, and 4). These NPC patients
recognized on average 2.1 epitopes per patient when LMP2-
speciﬁc CD8+ T cells were stimulated using peptides. In each case,
peptide-stimulated T cell lines recognized all of the epitopes
recognized by EBV-stimulated T cell lines, thus peptide stimulation
was inclusive of, but more comprehensive than, EBV stimulation.
Overall, peptide-stimulated CD8+ T cells from all NPC patients
recognized an average of 2.1 epitopes per NPC patient, and this
was signiﬁcantly more than the average number of epitopes
recognized by CD8+ T cells after stimulation with the patient's
own EBV-infected cells (Fig. 1C; 2.1 epitopes in LMP2 peptide-
stimulated T cell lines versus 1.1 epitopes in EBV-stimulated T cell
lines, p¼0.0008 paired Students t test).donors. The number of distinct LMP2 epitopes recognized by PBMC from individual
a pool of overlapping LMP2 peptides (white bars). LMP2 epitopes in the T cell lines
the average number of LMP2 epitopes in T cell lines stimulated with EBV or peptide
M. Fogg et al. / Virology 441 (2013) 107–113 109Similar experiments were carried out using PBMC from healthy,
EBV seropositive donors, and the same number and sequence of
LMP2 epitopes were recognized by EBV-stimulated (Fig. 1B, black
bars) as peptide-stimulated (Fig. 1B, white bars) T cell lines in all
cases studied, i.e. EBV stimulation was as comprehensive as
peptide stimulation in healthy donors. Overall, the average num-
ber of LMP2 epitopes recognized in EBV-stimulated T cell lines
from healthy donors was 2.6 (Fig. 1B, black bars), and the average
number of LMP2 epitopes recognized by peptide-stimulated T cell
lines was 2.7 per donor (Fig. 1B, white bars). Thus, NPC patients
have a similar capacity of LMP2-speciﬁc CD8+ T cells as healthy
donors (Fig. 1C, 2.1 versus 2.7 epitopes for NPC versus healthy
donors after peptide stimulation; compare white bars), but LMP2-
speciﬁc CD8+ T cells from NPC patients responded abnormally
when stimulated by EBV-infected cells with recognition of sig-
niﬁcantly fewer epitopes (Fig. 1C; compare black bars, 1.1 versus
2.6 epitopes, p¼0.0003 Students t test).
Depletion of Tregs augments EBV-speciﬁc CD8+ T cell responses
in EBV-stimulated T cell lines generated from NPC patients
We investigated whether Tregs were responsible for the
abnormal response of EBV-speciﬁc CD8+ T cell responses in NPC
patients. First, we asked whether CD4+ T cells might contain a
population of suppressor cells by depleting CD4+ T cells from the
PBMC of NPC patients (greater than 97% of CD4+ T cells were
selectively removed from PBMC by immunomagnetic depletion),
and then repetitively stimulating the CD4-depleted PBMC with LCL
to generate EBV-stimulated T cell lines. We had sufﬁcient PBMC for
cell depletion studies in 5 NPC patients (NPC6, 9, 14, 15, and 17)
with abnormal EBNA-1-speciﬁc CD8+ T cell responses (Supple-
mentary Table 1). The abnormal EBNA-1 response in NPC patients
is readily detected by an absent/present EBNA-1 response in EBV-
versus peptide-stimulated T cells since the EBNA-1-speciﬁc CD8+
T cell response is usually limited to recognition of a single dominant
epitope (Fogg et al., 2009). As expected from the depletion of helper
T cells, the total cell numbers were reduced in EBV-stimulated T cell
lines derived from CD4-depleted PBMC (average 3-fold increase,
range 2–6 fold) compared to non-depleted PBMC (average 16-fold
increase, range 3–32). Despite the smaller in vitro expansion, EBNA-
1-speciﬁc CD8+ T cells responses were rescued in 3 of 5 T cell lines
generated from CD4-depleted PBMC (NPC6, 15, and 17, Fig. 2, black
bars), whereas EBNA-1-speciﬁc T cell responses remained unde-
tectable in mock-depleted T cell lines where CD4+ T cells were
present (Fig. 2, white bars).
To more speciﬁcally identify whether the inhibitory cells in the
CD4+ T cell population were Tregs, cells expressing the IL-2
receptor alpha chain at high levels (CD25hi) were immunode-
pleted from PBMC prior to generation of EBV-stimulated T cell
lines from the same 5 NPC patients. Immunomagnetic depletion ofFig. 2. EBNA-1-speciﬁc CD8+ T cell responses can be rescued by removal of CD4+
or CD25(hi) T cells from NPC PBMC. PBMC depleted of CD4+ T cell lines (black bars),
CD25hi cells (hatched bars), or non-depleted PBMC (white bars) were stimulated
with LCL and EBNA-1 speciﬁc CD8+ T cell responses were detected by IFN-γ
ELISPOT after incubation with an EBNA-1 peptide pool. Results from a representa-
tive experiment are expressed as the number of EBNA-1-speciﬁc spot forming cells
(SFC) per million input cells.CD25hi cells resulted in 466% decrease of CD4+ CD25hi staining
cells in all cases (range 66%–78%) with a concurrent 471%
decrease in FoxP3 positive cells (range 71%–82%), a representative
FACS plot is shown in Fig. 3A. CD25hi depleted PBMC were
repetitively stimulated with EBV-infected cells to generate EBV-
stimulated T cell lines (average 11-fold increase in cells; range 2–
18 fold). EBNA-1-speciﬁc CD8+ T cell responses were restored
using CD25hi depleted PBMC from the same 3 of 5 NPC patients
(Fig. 2, hatched bars, NPC6, 15, and 17) where CD4+ T cell
depletion also restored EBNA-1-speciﬁc T cell responses. Thus,
depletion of CD4+ T cells, and speciﬁcally CD25hi cells, can restore
EBNA-1-speciﬁc CD8+ T cell responses to EBV-infected cells in a
subset of NPC patients in vitro, consistent with Treg-mediated
immune suppression of anti-tumor responses in some NPC
patients.
Pharmacologic mediated depletion of Tregs enhances EBV-speciﬁc
T cell responses in EBV-stimulated T cell lines generated from NPC
patients
To investigate a more readily translatable approach to reverse
Treg-mediated suppression of anti-tumor responses in NPC
patients, we tested whether a clinically approved drug targeting
Tregs could reverse suppression of EBV-speciﬁc immune responses
in vitro. Ontak (denileukin diftitox) is a recombinant protein
consisting of the human interleukin 2 sequence genetically fused
to the catalytic and transmembrane domains of diphtheria toxin,
thereby speciﬁcally targeting cells expressing CD25 for toxin
mediated cell killing (Williams et al., 1990). As shown in Fig. 3,
overnight treatment NPC PBMC with 5 mM Ontak reduced the
number of CD4+/CD25hi T cells from 9.44% to 5.61% and the
number of CD25hi/FoxP3+ cells from 10.3% to 7.25%. Thus, Ontak
treatment does eliminate cells with a Treg phenotype and the
average Ontak mediated reduction was 48% (range 27%–56%; n¼6)
for CD4+/CD25hi T cells and 44% (range 26%–58%; n¼6) for
CD25hi/FoxP3+ T cells. This analysis likely underestimates the
actual Treg depletion since the in vitro culture of PBMC can also
stimulate a new CD25hi/FoxP3+ activated T cell population that
masks the loss of CD25hi/FoxP3+ Tregs.
Ontak or mock treated PBMC were repetitively stimulated with
LCL to generate EBV-stimulated T cell lines from 11 NPC patients
with abnormal EBNA-1-speciﬁc CD8+ T cell responses to EBV-
infected cells, and one patient with intact EBNA-1 responses to
both EBV-infected cells and peptides. The T cell expansion was
slightly greater with Ontak versus mock treated PBMC (average
8-fold increase, range 3–18, versus 6-fold increase, range 2–13).
There was no signiﬁcant difference in the phenotype of the T cell
lines derived from Ontak or mock treated PBMC (average 89% CD3
+, 69% CD8+, and 19% CD4+).
EBNA-1-speciﬁc CD8+ T cell responses to EBV-infected cells
were restored by Ontak treatment of PBMC in 7 of the 11 NPC
patients with abnormal EBNA-1-speciﬁc immune responses
(Fig. 4A, black bars, NPC6, 13, 15, 17, 27, 29, and 43). No EBNA-1-
speciﬁc T cell responses were detected in EBV-stimulated T cell
lines derived from their mock treated PBMC (Fig. 4A, open bars).
Ontak did not have an adverse effect on EBNA-1-speciﬁc responses
in NPC patient 26 who had an intact EBNA-1 speciﬁc response to
EBV and peptide stimulation. Ontak treatment of PBMC did not
rescue EBNA-1-speciﬁc CD8+ T cell responses in the remaining
four patients (NPC9, 12, 14, 31).
In 9 of 12 patients the effect of Ontak on the LMP2-speciﬁc CD8
+ T cell response was also determined (Fig. 4B). Ontak treatment of
PBMC led to an increased repertoire of LMP2-speciﬁc CD8+ T cells
in response to EBV-infected cells in four NPC patients (NPC6, 9, 26,
and 27). Ontak treatment of PBMC did not increase the repertoire
of LMP2-speciﬁc T cells in the other ﬁve NPC patients (NPC12, 13,
Fig. 3. Ontak treatment of NPC PBMC reduces CD4+ T cells with a Treg phenotype. NPC PBMC were treated overnight with 5 mM Ontak. The percent of CD25hi cells (top
panels) and CD25hi/FoxP3+ cells (bottom panels) was determined pre- (left panels) and post-Ontak treatment (right panels).
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responses, either EBNA-1, LMP2, or both, in 9 of 12 NPC patients.
Ontak enhances immune control of EBV-infected cells
by PBMC from NPC patients
We next asked whether Ontak treatment of PBMC from NPC
patients translates into improved immune control of EBV-infected
cells as a surrogate measure for improved anti-tumor responses
in vivo. Moss et al. (1983) reported impaired EBV-speciﬁc immunity
in NPC patients detectable by an in vitro regression assay. In this
assay, PBMC are infected with EBV in vitro, and multiple replicates
of PBMC are cultured at decreasing numbers, so that T cells are
present in gradually limiting numbers. EBV infection immortalizes B
cell growth, and the minimum number of EBV-speciﬁc T cells
necessary to mediate control, or regression, of EBV-immortalized
B cell growth is a reﬂection of EBV-speciﬁc immunity, i.e. fewer
T cells are required to control growth when EBV-speciﬁc immune
responses are more robust.
Regression assays from ﬁve healthy donors showed an average of
28,223 PBMC were required to control growth of EBV-infected cells in
50% of the replicates, whereas PBMC from eight NPC patients showed
76,828 PBMC were required for 50% regression (Fig. 5, compare blacksquares with black circles, p¼0.05 Mann-Whitney U test). These
results are similar to those described by Moss et al. (1983). The level
of EBV immune responses are variable from person-to-person, but an
increased number of PBMC from NPC patients overall are required to
efﬁciently control EBV infection, i.e. the T cell response in NPC patients
is less effective at controlling EBV infection.
Ontak treatment of PBMC from seven NPC patients improved
the regression value from an average of 80,550–41,445 PBMC
(Fig. 5, compare black circles with shaded circles), a signiﬁcant
recovery in the average regression value (49%, p¼0.038, paired
Students t test). There was no signiﬁcant effect following Ontak
treatment of PBMC from three healthy donors (average of 29,197–
27,841 following treatment, p¼0.6). Thus, Ontak can reverse
suppression of EBV-speciﬁc T cell responses, resulting in a sig-
niﬁcant overall improvement in immune control of EBV-infected
cells in vitro by NPC patients.Discussion
In the current study, we found: (1) EBV-speciﬁc CD8+ T cell
responses to LMP2, a viral protein expressed in most EBV-associated
malignancies, are abnormal in many NPC patients, (2) Tregs (CD25hi
Fig. 4. Ontak treatment of PBMC from NPC patients rescues EBNA-1 and LMP2-
speciﬁc CD8+ T cell responses. PBMC from NPC patients were treated overnight
with Ontak (black bars) or mock treated (white bars), and then stimulated with
EBV-infected cells to generate T cell lines. EBNA-1- and LMP2-speciﬁc T cell
responses present in the T cell lines were detected by IFN-γ ELISPOT using either
an EBNA-1 peptide pool (A) to determine the number of EBNA-1-speciﬁc spot
forming cells (SFC) per million input cells, or LMP2 peptide pools (B) to determine
the number of individual LMP2 epitopes recognized.
M. Fogg et al. / Virology 441 (2013) 107–113 111cells) suppress both EBNA-1- and LMP2-speciﬁc CD8+ T cell
responses in NPC patients, (3) physical Treg depletion or pharma-
cologic therapy with Ontak removes suppression and restores EBV-
speciﬁc CD8+ T cell responses from many NPC patients and (4)
Ontak treatment of PBMC from NPC patients results in enhanced
in vitro immune control of EBV-infected cells.
Tregs are a physiologic response to chronic antigen stimulation in
persistent virus infections such as Hepatitis B and C (Xu et al., 2006;
Cabrera et al., 2004), as well as EBV (Marshall et al., 2003; Voo et al.,
2005). Voo et al. (2005) identiﬁed EBNA-1-speciﬁc CD4+ T cell
clones with a Treg phenotype in healthy, EBV seropositive indivi-
duals that could suppress anti-CD3 induced cell proliferation. In our
assay system, we did not see any functional evidence of Treg-
mediated suppression in healthy individuals, suggesting that the
Tregs in our NPC patients were either more abundant or active
compared to healthy donors with normal persistent EBV infection. In
our in vitro model, PBMC are co-cultured with EBV-infected cells to
stimulate the expansion of EBNA-1- and LMP2-speciﬁc CD8+ T cells.
Tregs in the PBMC of NPC patients may already be pre-activated
in vivo or may be activated upon exposure to the EBV-infected cell
in vitro; either may prevent the expansion of EBNA-1 and LMP2-
speciﬁc CD8+ T cells. It is also a possibility that Tregs suppress the
CD8+ T cell activity detected in ELISPOT assays, although this would
require that the Tregs be propagated for weeks in EBV-stimulated
T cell lines. EBV-speciﬁc responses may not be suppressed after
peptide and cytokine stimulation because EBV-infected cells are not
present to activate Tregs, or the potent stimulation of CD8+ T cells in
the presence of cytokines may simply override the Treg suppressive
effect.This excessive Treg activity in NPC patients may arise through
their continuous stimulation from the high antigenic load asso-
ciated with the presence of an EBV-positive tumor. Alternatively,
increased Treg numbers or function could be a primary event that
contributes to the development of malignancy, i.e. those indivi-
duals with higher Treg activity during persistent EBV infection
may be at increased risk for EBV-associated cancers due excessive
Treg suppression of EBV immunity.
Tregs have been described and implicated in EBV-associated
NPC. Li et al. (2011a) found higher numbers of CD4+ CD25+ cells in
the peripheral blood of 67 NPC patients compared to 20 healthy
donors (47% versus 2.8%). Cells of a Treg phenotype can also be
found in NPC tumor inﬁltrates (Lau et al., 2007), and the same
study also found increased levels of circulating Tregs in the
peripheral blood of NPC patients compared to healthy controls.
More recently, Li et al. (2011b) described CD8+ Tregs present at
increased frequencies in the peripheral blood of NPC patients
compared to healthy controls, and these cells could also be
detected in the tumor inﬁltrate. Our study signiﬁcantly extends
these observations by demonstrating a functional consequence of
Tregs on EBV- and tumor-speciﬁc CD8+ T cell responses in NPC
patients. Furthermore, we show that removing the Treg suppres-
sion from PBMC of NPC patients can result in enhanced control of
the patient's own EBV-infected cells. It remains to be determined
whether Tregs in NPC patients are EBV-speciﬁc in terms of their
activation and effector function. We were not able to rescue
tumor-speciﬁc T cell responses in all NPC patients. In these non-
responding cases, suppression may be due to mechanisms not
involving Tregs, or tumor-speciﬁc CD8+ T cell responses may have
been suppressed in these patients beyond a point of recovery.
The rescue of EBV-speciﬁc responses in NPC patients by removing
Treg-mediated suppression with Ontak has important clinical implica-
tions that could be readily translated and tested in NPC patients.
Historically, Ontak has had limited clinical efﬁcacy in melanoma trials
where it was used in attempts to break tolerance to self-antigens
expressed on tumor cells (Mahnke et al., 2007; Morse et al., 2008).
However, the immunobiology of NPC is quite different since EBV-
speciﬁc CD8+ T cells already exist in patients, and once Treg suppres-
sion is removed by Ontak the anti-tumor cells might be readily
expanded. Thus, there are several therapeutic models that could be
tested. Simply treating patients with Ontak, or other agents that target
Tregs, may result in expansion of tumor-speciﬁc CD8+ T cells in vivo,
as we have modeled in vitro, resulting in a direct clinical effect against
the tumor. Alternatively, Ontak may be useful as an adjuvant to
adoptive immunotherapy using EBV-speciﬁc T cells. Pretreatment of
NPC patients with Ontak could increase the number of tumor-speciﬁc
CD8+ T cells in the peripheral blood so that in vitro expansion of EBV-
speciﬁc T cells produces a more robust EBV-speciﬁc T cell product,
containing increased EBNA-1 and LMP2-speciﬁc CD8+ T cells for
adoptive transfer. Ontak may provide additional beneﬁt by removing
the immunosuppressive element from the tumor microenvironment,
allowing for more effective killing at the tumor site after adoptive
transfer of EBV-speciﬁc T cells.
In conclusion, we show that the EBV- and tumor-speciﬁc CD8+
T cell response is suppressed in many NPC patients, it is salvage-
able by the depletion of Tregs, and Ontak mediated removal of
Treg immunosuppression may be a viable and effective therapy to
enhance anti-tumor responses in EBV-associated NPC.Materials and methods
Human subjects
Peripheral blood was obtained by informed consent from
healthy donors under an IRB approved protocol at Brigham and
Fig. 5. Ontak treatment of NPC PBMC restores EBV immunity detected by enhanced regression of EBV-induced cell growth. PBMC from healthy donors (squares) and NPC
patients (circles) were treated overnight with Ontak (shaded) or mock treated (black). PBMC were then infected with EBV, replicate plated at varying cell numbers, and
scored for outgrowth of EBV-infected cells after several weeks in culture. The cell number where 50% of replicates showed outgrowth of EBV-infected cells, i.e. 50%
regression, was calculated according to the formula of Reed and Muench. Signiﬁcance between healthy donors and NPC patients was determined by Mann-Whitney U test,
and signiﬁcance of Ontak treatment by paired Students t test.
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with EBV-associated NPC conﬁrmed by EBER in situ hybridization
under an IRB approved protocol at the Dana Farber Cancer
Institute.
Peptides
102 peptides spanning EBNA-1 (15mer peptides overlapping by
11 residues, spanning the N-terminal 96 and C-terminal 334
residues) and 97 peptides spanning LMP2 (15mers and one
12mer, overlapping by 10 residues) were synthesized by F-moc
chemistry at the Massachusetts General Hospital peptide core
facility (Charlestown, MA). Individual peptides were resuspended
at 100 mg/ml in 100% DMSO (Sigma). The ﬁnal concentration used
for stimulation in pools, or as individual peptides, was 1–2 μg/ml.
Peripheral blood mononuclear cell puriﬁcation, EBV transformed
B cell line generation, and T cell subset depletion
PBMC were separated from heparinized blood by density
centrifugation. Autologous EBV transformed lymphoblastoid B cell
lines (LCL) were generated by incubation of PBMC with super-
natant from the B95-8 cell line (Miller and Lipman, 1973). CD4+ or
CD25+ cells were depleted from PBMC by immunomagnetic
selection (Dynal). Efﬁcient depletion was conﬁrmed by ﬂow
cytometric analysis on a FACSCalibur (BD Biosciences) using
T cell-speciﬁc, ﬂuorescently-conjugated antibodies (Biolegend)
and analyzed using FlowJo software (TreeStar).
EBV-stimulated and peptide-stimulated T cell lines
T cell lines were generated as described previously (Fogg et al.,
2009; Blake et al., 2000; Straathof et al., 2005). EBV-stimulated
T cell lines were generated by stimulation of PBMC with irradiated
autologous LCL at a ratio of 40:1 for 10 days at 37 1C with 5% CO2,
followed by three subsequent stimulations at 4:1 every seven days.
20 IU/ml IL-2 (Roche) was added after the second stimulation and
maintained in the culture medium. Peptide-stimulated T cell lines
were generated by pulsing PBMC with peptide for 1 h, and then
PBMC were washed and cultured in media containing 25 ng/ml IL-7
(R&D Systems). After three days, IL-2 was added at a ﬁnal concen-
tration of 10 IU/ml, and cultures were subsequently fed every three
days with fresh medium containing IL-2 and IL-7. Cells were
harvested for analysis after 10–14 days in culture.Pharmacologic mediated depletion of CD25 expressing cells
PBMC were treated overnight with 5 mM of DAB389IL-2
(Ontak) (Williams et al., 1990) at 37 1C with 5% CO2. Cells were
recovered on the following day and washed three times prior to
the generation of EBV-stimulated T cell lines.
Measurement of EBNA-1 and LMP2-speciﬁc T cell responses
and epitopes
Peptide-speciﬁc T cells were enumerated by incubating CD4+ T
cell depleted cell populations with peptide overnight at 37 1C with
5% CO2, and then detecting interferon γ secretion by ELISPOT
assays as described (Fogg et al., 2009) and following the manu-
facturer's instructions (Mabtech). The number of activated T cells
was measured by counting spots of interferon-γ secretion using an
automated reader and analysis software (Zellnet, NJ). Background
values of cells incubated with no peptide or control peptides were
subtracted from all test samples. Results are expressed as spot
forming cells (SFC) per million cells, and a response greater than
50 SFC per million cells was considered positive. Individual LMP2
epitopes were identiﬁed by positive responses to distinct, non-
overlapping peptides. Responses to two overlapping peptides were
recorded as a single epitope.
Regression assay
Regression assays were performed as described (Moss et al.,
1983). PBMC were incubated with ﬁltered viral supernatant from
the B95-8 cell line, washed and seeded at a range of doubling
dilutions, in multiple replicates, in a 96 well ﬂat-bottomed plate.
Cultures were incubated at 37 1C with 5% CO2 with weekly changes
of medium. After four to ﬁve weeks, wells were scored positive or
negative for growth of EBV transformed B cells and the cell
number required to achieve a 50% incidence of regression was
then calculated according to the formula of Reed and Muench
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